All In Biotech

Drug Trial Radar · NCT07340320

A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 251 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

251

Actual

Start

Feb 6, 2026

Primary completion

Apr 8, 2027

Study completion Apr 15, 2027

Sponsor

Lead sponsor
Corxel PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jan 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is testing whether a new medication called CX11 works and is safe for participants with type 2 diabetes who have not reached good blood sugar control while taking a steady dose of metformin, with or without a steady dose of an SGLT2 inhibitor, for at least 90 days. The study is being done at multiple medical centers. Participants are assigned by chance (randomized) to different groups, and neither the participants nor the study staff know which group they're in (double-blind). The groups are compared side by side (parallel), and some participants will receive inactive pills (placebo) to help measure the true effect of the study drug. After screening, participants will be randomly placed into one of six groups, with equal chances of being in any group. Each group will receive a different dose of CX11 or a placebo. Treatment will last 24 weeks. After that, all participants will have a 2-week follow-up period to check on safety.

Conditions

  • Type II Diabetes Mellitus

Interventions

  • CX11Drug

    CX11 tablets administered orally once daily (QD)

  • PlaceboOther

    Matching placebo tablets administered orally once daily (QD)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Glycosylated hemoglobin, Type A1C (HbA1c) from baselineTime frame: At Week 24

Locations

44 sites in 2 countries. Site status is shown where the registry gives one.

  • Central Research Associates - Flourish - PPDS

    Birmingham, Alabama

  • AES - DRS - Synexus Clinical Research US, Inc. - Birmingham

    Birmingham, Alabama

  • AES - DRS - Optimal Research Alabama - Huntsville

    Huntsville, Alabama

  • Core Healthcare Group

    Cerritos, California

  • Ark Clinical Research - Long Beach

    Long Beach, California

  • Flourish Research - Walnut Creek - PPDS

    Walnut Creek, California

  • AES - DRS - Optimal Research Florida - Melbourne

    Melbourne, Florida

  • Tampa General Hospital

    Tampa, Florida

  • Conquest Research LLC - Winter Park

    Winter Park, Florida

  • Privia Medical Group Georgia, LLC - Albany - Javara - PPDS

    Albany, Georgia

  • Javara Inc. - Fayetteville

    Fayetteville, Georgia

  • Privia Medical Group Georgia, LLC - Savannah - Javara - PPDS

    Savannah, Georgia

  • AES - DRS - Synexus Clinical Research US, Inc. - Chicago

    Chicago, Illinois

  • AES - DRS - Synexus Clinical Research US, Inc. - Evansville

    Evansville, Indiana

  • Privia Medical Group, LLC - Kelly's Collaborative Care - Javara - PPDS

    Silver Spring, Maryland

  • Elixia Health - Michigan Kidney Consultants, LLC - Elixia - PPDS

    Pontiac, Michigan

  • AES - DRS - Synexus Clinical Research US, Inc. - Edina - Minneapolis

    Edina, Minnesota

  • Mankato Clinic - East Main Street - Javara - PPDS

    Mankato, Minnesota

  • Sky Integrative Medical Center

    Ridgeland, Mississippi

  • Hassman Research Institute - Berlin - CenExel - PPDS

    Berlin, New Jersey

  • Albuquerque Clinical Trials Inc

    Albuquerque, New Mexico

  • Brooklyn Clinical Research

    Brooklyn, New York

  • M3 Wake Research, Inc - M3 WR

    Raleigh, North Carolina

  • M3 Wake Research - Dallas

    Dallas, Texas

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • SMS Clinical Research, LLC - 400 W. Kearney St

    Mesquite, Texas

  • AES - DRS - Synexus Clinical Research US, Inc. - San Antonio

    San Antonio, Texas

  • Flourish Research - San Antonio - PPDS

    San Antonio, Texas

  • Privia Medical Group- North Texas - Stephenville - Javara - PPDS

    Stephenville, Texas

  • Conquest Research - Arlington

    Vienna, Virginia

  • AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Poznaniu

    Poznan, Greater Poland Voivodeship, Poland

  • Centrum Medyczne Pratia Bydgoszcz - PPDS

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

  • Medyczne Centrum Diabetologiczno-Endokrynologiczno-Metaboliczne

    Krakow, Lesser Poland Voivodeship, Poland

  • FutureMeds - Krakow - PPDS

    Krakow, Lesser Poland Voivodeship, Poland

  • METABOLICA Sp. z o.o

    Tarnów, Lesser Poland Voivodeship, Poland

  • AES - DRS - Synexus Polska Sp. Z o.o. Oddzial w Lodzi

    Lodz, Lódzkie, Poland

  • FutureMeds - Lodz - PPDS

    Lodz, Lódzkie, Poland

  • AES - DRS - Synexus Polska Sp. z o.o. Oddzial we Wroclawiu

    Wroclaw, Lower Silesian Voivodeship, Poland

  • FutureMeds - Warszawa Centrum - PPDS

    Warsaw, Masovian Voivodeship, Poland

  • AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Warszawie

    Warsaw, Masovian Voivodeship, Poland

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.